 Home > Medical News > Medicines Company News > TJD5 announced that the results of the Phase 1 clinical study of TJD5 in the United States were selected for the ASCO annual meeting for display and report

TJD5 announced that the results of the Phase 1 clinical study of TJD5 in the United States were selected for the ASCO annual meeting for display and report

 Last Update: 2021-07-09
 Source: Internet
 Author: User

Tags

mirabegron mechanism action

thyroid cancer cured

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Tianjing Biologics is a biopharmaceutical company that is moving from the clinical stage to commercialization.
It is committed to the target biological research of innovative biological drugs, antibody technology, and clinical development and product commercialization in China and the United States.
It is a global cancer that is in urgent need.
In the treatment field, provide new and effective treatment methods
.

The company announced today that its self-developed and differentiated CD73 antibody uliledlimab (also known as TJD5) in the US Phase 1 clinical research results have been selected as the poster of the American Society of Clinical Oncology (ASCO) 2021 annual meeting, and selected as the report format at the conference Research data will be published during the period

Uliledlimab is an innovative CD73 humanized antibody that effectively relieves the immune suppression of the tumor microenvironment by inhibiting the production of adenosine to improve the systemic and tumor local immune response.
Preclinical studies have shown that it is a single agent or inhibits PD-(L)1 When used in combination, it can effectively inhibit tumor growth
.

The molecular differentiation advantage of Uliledlimab lies in its unique pharmacological mechanism of action, that is, by recognizing a unique epitope, and completely inhibiting the activity of CD73 in an "endo-dimer" binding mode, so as to achieve superior anti-tumor effects

At the 2021 American Society for Cancer Research (AACR) annual meeting, Cosmos Bio focused on showing the new protein structure and molecular mechanism of uliledlimab binding to CD73, as well as its single-drug and anti-PD-(L)1 antibody combination.
A series of preclinical data on tumor activity
.

Uliledlimab's global clinical development has made many major advances
.

In February 2021, Tianjing Biotechnology completed the preliminary evaluation of the results of the U.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.